Definigen
OverviewSuggest Edit
Definigen is a company that provides functional disease model human cells, including hepatocytes, pancreatic beta cells, and intestinal organoids. It develops OptiDIFF, a platform technology that focuses on induced pluripotent stem cell (iPSC) generation, CRISPR-Cas9 gene editing, iPSC differentiation, and custom disease model development. The company delivers its services across life science, drug discovery, and regenerative medicine sectors.
| Type | Private | |
| Founded | 2012 | |
| HQ | Babraham, GB | Map |
| Website | definigen.com |
Latest Updates
| Employees (est.) (May 2022) | 19 | (-5%) |
| Cybersecurity rating | C | More |
Key People/Management at Definigen
Ben Cons
Chairman
Marcus Yeo
Chief Executive Officer
Richard Willock
Chief Business Officer
Marek Gumienny
Non-Executive Director
Ludovic Vallier
Chief Scientific Officer
Chris Kirton
Chief Operating Officer
Definigen Office Locations
Definigen has an office in Babraham
Babraham, GB (HQ)
Babraham Research Campus Moneta Building B280
Definigen Financials and Metrics
Summary Metrics
Founding Date | 2012 |
Definigen total Funding | $9.1 m |
Definigen latest funding size | $886.77 k |
Time since last funding | 4 years ago |
Definigen investors | Jonathan Milner, Providence Investment Company Limited, University of Cambridge Enterprise, Cambridge Capital Group, Cambridge Angels group, 24 Haymarket, Parkwalk Advisors |
Definigen's latest funding round in November 2018 was reported to be $886.8 k. In total, Definigen has raised $9.1 m
Definigen Cybersecurity Score
Definigen Online and Social Media Presence
1.14k Twitter followers
Definigen has 1.14k Twitter Followers. The number of followers has decreased 0.2% month over month
Definigen's Trends
Definigen Blogs
January 20, 2022
DefiniGEN appoints Dr Chris Kirton as Chief Executive Officer
Cambridge, UK – Thursday 20th January 2022 – DefiniGEN is pleased to announce the appointment of Dr Chris Kirton as Chief Executive Officer. Chris has more than 16 years of operational experience and joined DefiniGEN as Chief Operating Officer in June 2020. The appointment is key for DefiniGEN a…
July 29, 2021
DefiniGEN Achieves ISO 9001: (2015) Certification
Cambridge July 29th, 2021: DefiniGEN, a provider of iPSC-derived products and disease modelling services, today announces that the company has earned ISO 9001: 2015 certification at its Cambridge UK facility. ISO certification confirms excellence in quality management standards and validates the com…
April 29, 2021
DefiniGEN appoints Dr Ben Cons as Chairman of its Board
Cambridge, UK- 29 April 2021: DefiniGEN, the world leader in human induced pluripotent stem cell (iPSC) differentiation and disease modelling, today announces the appointment of Dr Ben Cons as Chairman of the Board. A respected entrepreneur and pharmaceutical and healthcare leader, he has a prov…
November 19, 2020
DefiniGEN Secures £3.25 million in Funding to Fast-Track Growth
19th November 2020, Cambridge: DefiniGEN – a provider of human cell products and services – has closed a £3.25 million funding round to accelerate its next phase of growth. This includes £2 million from BGF, the UK’s most active investor, alongside its existing consortium of investors led by 24Hayma…
Definigen Frequently Asked Questions
When was Definigen founded?
Definigen was founded in 2012.
Who are Definigen key executives?
Definigen's key executives are Ben Cons, Marcus Yeo and Richard Willock.
How many employees does Definigen have?
Definigen has 19 employees.
Who are Definigen competitors?
Competitors of Definigen include SUN bioscience, Creyon Bio and Nuclera.
Where is Definigen headquarters?
Definigen headquarters is located at Babraham Research Campus Moneta Building B280, Babraham.
Where are Definigen offices?
Definigen has an office in Babraham.
How many offices does Definigen have?
Definigen has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies